Asset Details
Do you wish to reserve the book?
Mechanism-based inhibition of squalene epoxidase by phenothiazines for lipid metabolism disruption using repurposed antipsychotic drugs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mechanism-based inhibition of squalene epoxidase by phenothiazines for lipid metabolism disruption using repurposed antipsychotic drugs
Do you wish to request the book?
Mechanism-based inhibition of squalene epoxidase by phenothiazines for lipid metabolism disruption using repurposed antipsychotic drugs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mechanism-based inhibition of squalene epoxidase by phenothiazines for lipid metabolism disruption using repurposed antipsychotic drugs
2025
Overview
Squalene epoxidase (SQLE) is a crucial enzyme in the cholesterol-biosynthesis pathway and a promising target for treating cholesterol-related disorders. This study aimed to repurpose eighteen clinically approved phenothiazine antipsychotics as competitive SQLE inhibitors by integrating structure-based virtual screening, 200 ns molecular-dynamics simulations, MM/PBSA binding-energy calculations and
in vitro
enzyme assays. We first screened the 18 derivatives using molecular docking, structural/pharmacological diversity and ADMET analysis. Six compounds—ethopropazine, periciazine, piperacetazine, dixyrazine, fluphenazine and trifluoperazine—were prioritized for detailed MD simulations and MM/PBSA evaluation. Potential-energy-landscape analysis revealed that ethopropazine, periciazine and piperacetazine formed the most stable enzyme–ligand complexes, each occupying well-defined energy wells. Corresponding ΔG
total
values of − 27.05 ± 2.10 kcal mol⁻¹, − 27.84 ± 1.67 kcal mol⁻¹ and − 26.94 ± 1.82 kcal mol⁻¹ indicated high binding affinities.
In
vitro
assays confirmed potent SQLE inhibition, with IC₅₀ values of 1.69 ± 0.06 µM, 1.55 ± 0.13 µM and 1.44 ± 0.04 µM, respectively; kinetic studies established competitive inhibition with
K
i
values of 0.65–0.69 µM. The strong correlation between computational predictions and experimental data underscores the effectiveness of our integrated approach and identifies ethopropazine, periciazine and piperacetazine as promising lead compounds for further optimization and pre-clinical development as SQLE inhibitors.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/154
/ 631/45
/ 631/57
/ Antipsychotic Agents - chemistry
/ Antipsychotic Agents - pharmacology
/ Cancer
/ Enzyme Inhibitors - chemistry
/ Enzyme Inhibitors - pharmacology
/ Enzymes
/ Humanities and Social Sciences
/ Humans
/ Ligands
/ Lipid Metabolism - drug effects
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Phenothiazines - pharmacology
/ Proteins
/ Science
/ Squalene Monooxygenase - antagonists & inhibitors
/ Squalene Monooxygenase - chemistry
/ Squalene Monooxygenase - metabolism
/ Sterols
/ Toxicity
